Galcanezumab
Galcanezumab is a monoclonal antibody designed for the prevention of migraine. It is developed and marketed by Eli Lilly and Company under the brand name Emgality.
Mechanism of Action[edit | edit source]
Galcanezumab works by binding to calcitonin gene-related peptide (CGRP) and blocking its binding to the receptor. CGRP is a neuropeptide that plays a crucial role in the pathophysiology of migraine.
Clinical Use[edit | edit source]
Galcanezumab is used for the preventive treatment of migraine in adults. It is administered once a month as a subcutaneous injection.
Side Effects[edit | edit source]
The most common side effects of galcanezumab include injection site reactions, such as pain, redness, and itching, and constipation.
Clinical Trials[edit | edit source]
Several clinical trials have demonstrated the efficacy and safety of galcanezumab in the prevention of migraine. These include the EVOLVE-1, EVOLVE-2, and REGAIN studies.
See Also[edit | edit source]
References[edit | edit source]
Galcanezumab Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD